Download Files:
RRx-001
$144 – $990
Products Details
Product Description
– RRx-001, a hypoxia-selective epigenetic agent and studied as a radio- and chem-sensitizer, triggers apoptosis and overcomes agent resistance in myeloma. RRx-001 exhibits potent anti-tumor activity with minimal toxicity[1]. RRx-001 is a dual small molecule checkpoint inhibitor by downregulating CD47 and SIRP-α[2]. RRx-001 is a potent inhibitor of G6PD and shows potent antimalarial activity[3].
Web ID
– HY-16438
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C5H6BrN3O5
References
– [1]Das DS, et al. A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells. Leukemia. 2016 Nov;30(11):2187-2197.|[2]Cabrales P, et al. RRx-001 Acts as a Dual Small Molecule Checkpoint Inhibitor by Downregulating CD47 on Cancer Cells and SIRP-α on Monocytes/Macrophages. Transl Oncol. 2019 Apr;12(4):626-632.|[3]Yalcin O, et al. From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria. Malar J. 2015 May 28;14:218.
CAS Number
– 925206-65-1
Molecular Weight
– 268.02
Compound Purity
– 99.69
SMILES
– BrCC(N1CC([N+]([O-])=O)([N+]([O-])=O)C1)=O
Clinical Information
– Phase 3
Research Area
– Cancer; Infection; Inflammation/Immunology
Solubility
– DMSO : ≥ 100 mg/mL
Target
– Apoptosis;Parasite
Isoform
– Plasmodium
Pathway
– Anti-infection;Apoptosis
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
